All of the ESRs recruited by PET3D will be exposed to a variety of highly complementary research environments spanning different therapeutic areas: oncology, cardiovascular, neuroscience and all of the ESRs will spend at least one secondment in a different country and will have the opportunity to attend training events and consortium meetings in all of the 7 countries involved in PET3D.


Each ESR will be exposed to the following:

  • Cutting edge research training, technical training, generic skills training.
  • Cross-sectorial training – translational skills training, commercialisation.
  • Access to state of the art technologies in each of the beneficiary sites.
  • Transferrable and generic skills training – communications, presentation, writing, management, dissemination, intellectual property rights protection, dissemination and exploitation, ethical issues, entrepreneurial initiatives, CV writing and interview training available locally at each beneficiary site.
  • Strong collaborative bonds with each ESR, with supervisors and mentors and also with researchers in related fields, thereby laying the foundation for future continued European-wide research collaboration.


ESR1 - Host ABD

AZ, month 12, for 6 months,
For in vitro and ex-vivo profiling, and pharmacokinetic studies on 3H/14C versions of fatty acid analogues and CPT1 inhibitors.

ESR2 - Host ABD

AMS, month 30, for 3 months,
‘for exploring full antibody or nanobody versions of the tracer.

ESR3 - Host AMS

1. BER, month 9, for 3 months,
for design and synthesis of target compounds.

2. IMA, month 18, for 6 months,
for performing chemistry and animal studies, development of complementary skills (e.g. business, project management).

ESR4 - Host AMD

1. ABD, month 26, for 6 months,
for evaluation of clearing agent on in vivo behaviour proteins and peptides.

2. BRU, month 33, for 2 months,
for comparing BRU’s nanobody technology products to come to best practice.

ESR5 - Host BRU

1. ABD, month 7, for 4 months
to gain knowledge on 18F-FDR radiochemistry

2. IMA, month 24, for 6 months,
for GMP production, toxicity study, IMPD writing, training on IP.

ESR6 - Host BRU

AZ, month 22, for 6 months,
translational pre-clinical studies on radioisotope- and NIR-labelled nanobodies.

ESR7 - Host SAN

1. ABD, month 14, for 6 months,
to gain knowledge on pre-targeting strategies and related synthetic chemistry.

2. IMA, month 35, for 4 months,
to acquire skills in image quantification and kinetic modeling.

ESR8 - Host SAN

1. BRU, month 16, for 2 months,
to gain knowledge on nanobody technology.

2. AZ, month 28, for 6 months,
to bind an oncology compound from AstraZeneca to the NanoBite platform.

ESR9 - Host BER

AZ, month 18, for 6 months,
for biodistribution studies through micro-dosing and drug validation studies.

ESR10 - Host BER

IMA, month 29, for 6 months
for performing biodistribution studies and metabolite characterisation.

ESR11 - Host MUN

IMA, month 12, for 6 months
to study therapeutic modulation of neuroinflammation via pre-clinical PET imaging.

ESR12 - Host MUN

AZ, month 6, for 6 months
to study best modality of therapeutic intervention (e.g. anti-angiogenesis).

ESR13 - Host ABD

AMS, month 24, for 6 months
for performing PET imaging studies on pre-targeted click tracers.

ESR14 - Host IMA

1. BER, month 13, for 3 months
for studying a pre-targeted approach to hypoxia PET imaging.

2. MUN, month 25, for 3 months
for exploring a pre-targeted PET imaging approach to gliomas.

3. ICL, month 8 and month 20 for 2 months each
characterisation of the constructs.

ESR15 - Host AZ

ABD, Month 18, for 6 months
to develop a [18F]-labeled tracer and perform pre-clinical studies in vivo.


In addition to local training, this ETN offers cutting-edge Network-wide training opportunities, see overview in ‘Main Network Training Events & Conferences’.

Dissemination events are public conferences or symposia on:

  • hot scientific topics of interest to PET3D
  • transferrable skills/employability workshops
  • business-related events

These events will be of particular interest to radiopharmaceuticals/drug discovery stakeholders and students.

Schools are larger and structured training initiatives lasting from 2 days to 5 days.

Training events are smaller, 1-day training courses/workshops, which will be open to external participants and therefore will also represent dissemination opportunities.



IMPACT Article Published

    Link to ingentaconnect article.   The ESRs...


More information can be found here: ESR...



S2 – School on Radiopharmaceuticals in Drug Discovery

20 - 22 September  2017   PET3D 2-day...

S1 School on Radiopharmaceutical Development

27 February - 03 March 2017 PET3D 5-day training...